theheart.org: Thrombosis Risk news and education

The selected article could not be found. Try again later or contact administrator.

Brain/Kidney/Peripheral

AAA: Aspirin not warranted in healthy subjects with low ABI, based on population screening

5 COMMENTS - Mar 2, 2010 16:00 EST

Authors of the study say their study does not rule out a role for ankle/brachial index screening in the clinic or for other CVD drugs to reduce risk in asymptomatic subjects. But for aspirin and for populationwide screening, the study raises some questions.

Edinburgh, UK - Results of the Aspirin for Asymptomatic Atherosclerosis (AAA) trial, showing no reduction in vascular events in asymptomatic subjects with a low ankle/brachial index (ABI) randomized to daily aspirin, have now been published in the March 3, 2010 issue of the Journal of the American Medical Association [1]. First presented at the ESC 2009 meeting and reported there by heartwire, the trial adds to mounting evidence that the risks of aspirin may outweigh its benefits in people without established cardiovascular disease. Read full article »

Inside: Thrombosis

Accredited educational programs, supported by industry, developed by theheart.org

Thrombosis

Secondary Prevention of Venous Thromboembolism: Current Controversies and Emerging Therapies

Mar 10, 2010 16:26 EST

Venous thromboembolism (VTE), a common but preventable disease, is associated with significant mortality and morbidity. Patients who have had a primary VTE event are at an increased risk for recurrence, but the risk is not uniform and secondary prophylaxis is associated with bleeding risk. The challenge then is to identify patients at high risk for recurrence who would benefit the most from extended secondary prophylaxis. Dr. Alexander G. G. Turpie presents a clinical update on the issues surrounding this rapidly evolving area and the agents in clinical development which have the potential to replace existing therapies.

Thrombosis

Preventing Symptomatic, Recurrent Deep Vein Thrombosis or Pulmonary Embolism: The Need for Long-Term Thromboprophylaxis

Dec 23, 2009 11:49 EST

Join Dr. Graham Turpie as he discusses exciting new data on novel oral anticoagulation therapy released at ASH.

Thrombosis

Best practices in VTE prophylaxis: apply the guidelines in patients with cancer

Jan 29, 2010 14:06 EST

Dr. Khorana summarizes the risk factors for VTE in patients with cancer and describes the current strategies for prophylaxis.

Acute Coronary Syndromes

Meeting the Challenges in Long-Term Anticoagulation: Opportunities to Improve Patient Care

Aug 7, 2009 09:10 EDT

Management of long-term anticoagulation therapy in STEMI patients is challenging. Please join our expert panel, Drs. Elaine Hylek, Ander Cohen, Greg Lip, and Jack Ansell, as they discuss current challenges and strategies to optimize the benefit of and provide insights to the future of anticoagulation therapy.

Medscape Medical News

Clopidogrel receives boxed warning for reduced benefit in poor metabolizers

5 COMMENTS - Mar 12, 2010 17:42 EST

The warning will inform clinicians that tests are available to predict whether a patient will convert the drug to its active form based on the genetic profile of a key liver enzyme.

Interventional/Surgery

ISAR-DESIRE 2: No advantage, no downside to switching stents for DES in-stent restenosis

Mar 11, 2010 14:00 EST

Either a sirolimus-eluting stent or a paclitaxel-eluting stent are suitable choices for treating in-stent restenosis of a sirolimus-eluting stent. Whether plain old or drug-eluting-balloon angioplasty might also work remains an open question.

Thrombosis

RESPOND: Ticagrelor improves platelet inhibition in both clopidogrel responders and nonresponders

1 COMMENT - Mar 10, 2010 13:30 EST

The authors of the study also suggest that ticagrelor may inhibit platelets more effectively than prasugrel.

Hypertension

Overweight, obese gain greater benefit from BP lowering

Mar 8, 2010 16:00 EST

The overweight and obese should be more aggressively treated with antihypertensive therapy than normal-weight individuals, because they will derive greater benefit, a new analysis of the PROGRESS study suggests.

News

What's going to be hot at ACC 2010?

Mar 5, 2010 16:45 EST

Pack this up for your patients: program chairs say a patient-care focus means results of this year's line-up of late-breaking clinical trials will have immediate relevance to clinical practice. Highlights include two ACCORD analyses looking at blood pressure and lipids, the EVEREST II results with the MitraClip, the MM-WES study of warfarin genotyping, plus a range of DES, HF, and atrial-fibrillation studies that may help answer the question of what therapies work best and at the best price.

Interventional/Surgery

Weekend admission delays major cardiac procedures

Mar 5, 2010 12:30 EST

New figures from the Agency for Healthcare Research and Quality show that patients admitted to US hospitals on weekends tend to experience significant delays in receiving major cardiac procedures.

Thrombosis

Apixaban better than European enoxaparin regimen for preventing VTE

Mar 4, 2010 18:30 EST

The investigational anticoagulant apixaban is more effective than the dose of enoxaparin commonly used in Europe for preventing venous thromboembolism in those undergoing knee replacement, according to new study results.

Lipid/Metabolic

COX-2 inhibitors blunt "preconditioning" effect of statin

2 COMMENTS - Mar 1, 2010 17:00 EST

The COX-2 inhibitor celecoxib completely abolished the beneficial preconditioning effect of rosuvastatin in a small mechanistic study in human volunteers.

Medscape Medical News

Medicare will delay paying claims for two weeks

2 COMMENTS - Mar 1, 2010 12:00 EST

The move by Medicare is intended to blunt the effect of the 21.2% pay cut. If a fix is passed, CMS carriers will pay March claims that had been put on hold, at the current rate.

Medscape Medical News

Medicare pay cut of 21.2% to take effect Monday

6 COMMENTS - Feb 26, 2010 16:30 EST

Senate Democrats will not introduce legislation creating a new effective date for the reduction until next week, according to a spokesperson for Senate Majority Leader Harry Reid.

Prevention

US scientists begin to unravel the mystery of 9p21

Feb 25, 2010 09:30 EST

New research has shed some light on a hitherto-unsolved genetic mystery: how a common variation on chromosome 9p21, associated with an increased risk of early coronary artery disease, might exert its effects. But the scientists stress that more work will be needed to see whether the findings in mice translate into humans.

Clotblog with Dr Samuel Goldhaber

Anticoagulation "bridging" for patients with VTE

Fri Feb 26 12:50:00 EST 2010

View all »

Editorial Programs

Editorial series

Informed consent, clinical research, and patient care

Mar 11, 2010 14:20 EST

Does informed consent protect patients or shield researchers? Join the debate with Dr Bob Harrington and his guests Drs Deepak Bhatt and Harvey White.

Editorial series

Women in cardiology: Is gender an issue?

3 COMMENTS - Mar 4, 2010 10:15 EST

Do gender perceptions affect the way female physicians are treated in cardiology? Drs Melissa Walton-Shirley, Judith Hochman, Suzanne Oparil, and Lynne Warner Stevenson tackle this important question.

Editorial series

Public smoking bans and cardiovascular health

15 COMMENTS - Feb 25, 2010 15:25 EST

Studies suggest public smoking bans reduce the incidence of acute MI. So why is America not smoke-free? Dr Melissa Walton-Shirley discusses this important issue with the AHA's Nancy Brown and Dr Clyde Yancy.